|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Benson AB III, Abrams TA, Ben-Josef E,
Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica
MI, Davila R, et al: NCCN clinical practice guidelines in oncology:
Hepatobiliary cancers. J Natl Compr Canc Netw. 7:350–391. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kwon HJ, Byun JH, Kim JY, Hong GS, Won HJ,
Shin YM and Kim PN: Differentiation of small (≤2 cm) hepatocellular
carcinomas from small benign nodules in cirrhotic liver on
gadoxetic acid-enhanced and diffusion-weighted magnetic resonance
images. Abdom Imaging. 40:64–75. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yu NC, Chaudhari V, Raman SS, Lassman C,
Tong MJ, Busuttil RW and Lu DS: CT and MRI improve detection of
hepatocellular carcinoma, compared with ultrasound alone, in
patients with cirrhosis. Clin Gastroenterol Hepatol. 9:161–167.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhan HW, Xu W, Ye XJ, Zhao CL, Zhang H, Li
J, Yao Q and Zhang LJ: Application of FDG-PET for detection of
malignant lesions in patients with elevated blood tumor markers but
without a history of malignancy. Mol Med Rep. 2:837–842. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Delbeke D, Martin WH, Sandler MP, Chapman
WC, Wright JK Jr and Pinson CW: Evaluation of benign vs malignant
hepatic lesions with positron emission tomography. Arch Surg.
133:510–515. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Iwata Y, Shiomi S, Sasaki N, Jomura H,
Nishiguchi S, Seki S, Kawabe J and Ochi H: Clinical usefulness of
positron emission tomography with fluorine-18-fluorodeoxyglucose in
the diagnosis of liver tumors. Ann Nucl Med. 14:121–126. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hayakawa N, Nakamoto Y, Nakatani K, Hatano
E, Seo S, Higashi T, Saga T, Uemoto S and Togashi K: Clinical
utility and limitations of FDG PET in detecting recurrent
hepatocellular carcinoma in postoperative patients. Int J Clin
Oncol. 19:1020–1028. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen YK, Hsieh DS, Liao CS, Bai CH, Su CT,
Shen YY, Hsieh JF, Liao AC and Kao CH: Utility of FDG-PET for
investigating unexplained serum AFP elevation in patients with
suspected hepatocellular carcinoma recurrence. Anticancer Res.
25:4719–4725. 2005.PubMed/NCBI
|
|
10
|
Cheng G, Torigian DA, Zhuang H and Alavi
A: When should we recommend use of dual time-point and delayed
time-point imaging techniques in FDG PET? Eur J Nucl Med Mol
Imaging. 40:779–787. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Park JW, Kim JH, Kim SK, Kang KW, Park KW,
Choi JI, Lee WJ, Kim CM and Nam BH: A prospective evaluation of
18F-FDG and 11C-acetate PET/CT for detection
of primary and metastatic hepatocellular carcinoma. J Nucl Med.
49:1912–1921. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ho CL, Yu SC and Yeung DW:
11C-acetate PET imaging in hepatocellular carcinoma and
other liver masses. J Nucl Med. 44:213–221. 2003.PubMed/NCBI
|
|
13
|
Lam MG, Kwee TC, Basu S and Alavi A:
Underestimated role of 18F-FDG PET for HCC evaluation
and promise of 18F-FDG PET/MR imaging in this setting. J
Nucl Med. 54:1510–1511. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cheung TT, Ho CL, Chen S, Chan SC, Poon
RT, Fan ST and Lo CM: Reply: Underestimated role of
18F-FDG PET for HCC evaluation and promise of
18F-FDG PET/MR imaging in this setting. J Nucl Med.
54:1511–1512. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tichauer KM, Wang Y, Pogue BW and Liu JT:
Quantitative in vivo cell-surface receptor imaging in oncology:
Kinetic modeling and paired-agent principles from nuclear medicine
and optical imaging. Phys Med Biol. 60:R239–R269. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sharma B, Martin A and Zerizer I: Positron
emission tomography-computed tomography in liver imaging. Semin
Ultrasound CT MR:. 34:66–80. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Izuishi K, Yamamoto Y, Mori H, Kameyama R,
Fujihara S, Masaki T and Suzuki Y: Molecular mechanisms of
[18F]fluorodeoxyglucose accumulation in liver cancer.
Oncol Rep. 31:701–706. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang Q, Wang J, Zhang H, Zhao D, Zhang Z
and Zhang S: Expression and clinical significance of aminopeptidase
N/CD13 in non-small cell lung cancer. J Cancer Res Ther.
11:223–228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wickström MI, Larsson R, Nygren P and
Gullbo J: Aminopeptidase N (CD13) as a target for cancer
chemotherapy. Cancer Sci. 102:501–508. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ikeda N, Nakajima Y, Tokuhara T, Hattori
N, Sho M, Kanehiro H and Miyake M: Clinical significance of
aminopeptidase N/CD13 expression in human pancreatic carcinoma.
Clin Cancer Res. 9:1503–1508. 2003.PubMed/NCBI
|
|
21
|
Fukasawa K, Fujii H, Saitoh Y, Koizumi K,
Aozuka Y, Sekine K, Yamada M, Saiki I and Nishikawa K:
Aminopeptidase N (APN/CD13) is selectively expressed in vascular
endothelial cells and plays multiple roles in angiogenesis. Cancer
Lett. 243:135–143. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Su L, Cao J, Jia Y, Zhang X, Fang H and Xu
W: Development of synthetic aminopeptidase N/CD13 inhibitors to
overcome cancer metastasis and angiogenesis. ACS Med Chem Lett.
3:959–964. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rocken C, Licht J, Roessner A and
Carl-McGrath S: Canalicular immunostaining of aminopeptidase N
(CD13) as a diagnostic marker for hepatocellular carcinoma. J Clin
Pathol. 58:1069–1075. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nagano H, Ishii H, Marubashi S, Haraguchi
N, Eguchi H, Doki Y and Mori M: Novel therapeutic target for cancer
stem cells in hepatocellular carcinoma. J Hepatobiliary Pancreat
Sci. 19:600–605. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Röcken C, Carl-McGrath S, Gräntzdörffer I,
Mantke R, Roessner A and Lendeckel U: Ectopeptidases are
differentially expressed in hepatocellular carcinomas. Int J Oncol.
24:487–495. 2004.PubMed/NCBI
|
|
26
|
Corti A, Curnis F, Arap W and Pasqualini
R: The neovasculature homing motif NGR: More than meets the eye.
Blood. 112:2628–2635. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen K, Ma W, Li G, Wang J, Yang W, Yap
LP, Hughes LD, Park R and Conti PS: Synthesis and evaluation of
64Cu-labeled monomeric and dimeric NGR peptides for
MicroPET imaging of CD13 receptor expression. Mol Pharm.
10:417–427. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang J, Lu X, Wan N, Hua Z, Wang Z, Huang
H, Yang M and Wang F: 68Ga-DOTA-NGR as a novel molecular
probe for APN-positive tumor imaging using MicroPET. Nucl Med Biol.
41:268–275. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mate G, Kertesz I, Enyedi KN, Mező G,
Angyal J, Vasas N, Kis A, Szabó É, Emri M, Bíró T, et al: In vivo
imaging of Aminopeptidase N (CD13) receptors in experimental renal
tumors using the novel radiotracer 68Ga-NOTA-c(NGR). Eur
J Pharm Sci. 69:61–71. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shao Y, Liang W, Kang F, Yang W, Ma X, Li
G, Zong S, Chen K and Wang J: A direct comparison of tumor
angiogenesis with 68Ga-labeled NGR and RGD peptides in
HT-1080 tumor xenografts using microPET imaging. Amino Acids.
46:2355–2364. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kang F, Ma W, Ma X, Shao Y, Yang W, Chen
X, Li L and Wang J: Propranolol inhibits glucose metabolism and
18F-FDG uptake of breast cancer through
posttranscriptional downregulation of hexokinase-2. J Nucl Med.
55:439–445. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao M, Yang W, Zhang M, Li G, Wang S,
Wang Z, Ma X, Kang F and Wang J: Evaluation of
68Ga-labeled iNGR peptide with tumor-penetrating motif
for microPET imaging of CD13-positive tumor xenografts. Tumour
Biol. 37:12123–12131. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Alberici L, Roth L, Sugahara KN, Agemy L,
Kotamraju VR, Teesalu T, Bordignon C, Traversari C, Rizzardi GP and
Ruoslahti E: De novo design of a tumor-penetrating peptide. Cancer
Res. 73:804–812. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen H, Niu G, Wu H and Chen X: Clinical
application of radiolabeled RGD peptides for PET imaging of
integrin αvβ3. Theranostics. 6:78–92. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ma W, Shao Y, Yang W, Li G, Zhang Y, Zhang
M, Zuo C, Chen K and Wang J: Evaluation of 188Re-labeled
NGR-VEGI protein for radioimaging and radiotherapy in mice bearing
human fibrosarcoma HT-1080 xenografts. Tumour Biol. 37:9121–9129.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tillmanns J, Schneider M, Fraccarollo D,
Schmitto JD, Länger F, Richter D, Bauersachs J and Samnick S: PET
imaging of cardiac wound healing using a novel
[68Ga]-labeled NGR probe in rat myocardial infarction.
Mol Imaging Biol. 17:76–86. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hendrikx G, De Saint-Hubert M, Dijkgraaf
I, Bauwens M, Douma K, Wierts R, Pooters I, Van den Akker NM,
Hackeng TM, Post MJ, et al: Molecular imaging of angiogenesis after
myocardial infarction by 111In-DTPA-cNGR and
99mTc-sestamibi dual-isotope myocardial SPECT. EJNMMI
Res. 5:22015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zheng K, Liang N, Zhang J, Lang L, Zhang
W, Li S, Zhao J, Niu G, Li F, Zhu Z, et al:
68Ga-NOTA-PRGD2 PET/CT for integrin imaging in patients
with lung cancer. J Nucl Med. 56:1823–1827. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wan W, Guo N, Pan D, Yu C, Weng Y, Luo S,
Ding H, Xu Y, Wang L, Lang L, et al: First experience of
18F-alfatide in lung cancer patients using a new
lyophilized kit for rapid radiofluorination. J Nucl Med.
54:691–698. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kang F, Wang S, Tian F, Zhao M, Zhang M,
Wang Z, Li G, Liu C, Yang W, Li X, et al: Comparing the diagnostic
potential of 68Ga-Alfatide II and 18F-FDG in
differentiating between non-small cell lung cancer and
tuberculosis. J Nucl Med. 57:672–677. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yu C, Pan D, Mi B, Xu Y, Lang L, Niu G,
Yang M, Wan W and Chen X: 18F-Alfatide II PET/CT in
healthy human volunteers and patients with brain metastases. Eur J
Nucl Med Mol Imaging. 42:2021–2028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Iagaru A, Mosci C, Shen B, Chin FT, Mittra
E, Telli ML and Gambhir SS: 18F-FPPRGD2 PET/CT: Pilot
phase evaluation of breast cancer patients. Radiology. 273:549–559.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhu Z, Yin Y, Zheng K, Li F, Chen X, Zhang
F and Zhang X: Evaluation of synovial angiogenesis in patients with
rheumatoid arthritis using 68Ga-PRGD2 PET/CT: A
prospective proof-of-concept cohort study. Ann Rheum Dis.
73:1269–1272. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Haubner R, Finkenstedt A, Stegmayr A,
Rangger C, Decristoforo C, Zoller H and Virgolini IJ:
[68Ga]NODAGA-RGD - Metabolic stability, biodistribution,
and dosimetry data from patients with hepatocellular carcinoma and
liver cirrhosis. Eur J Nucl Med Mol Imaging. 43:2005–2013. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sherigar JM, Gayam V, Khan A, Mukhtar O,
Arefiev Y, Khalid M, Siddiqui I, Rangaraju AM, Budhathoki N,
Mansour M, et al: Clinical efficacy and tolerability of
direct-acting antivirals in elderly patients with chronic hepatitis
C. Eur J Gastroenterol Hepatol. 29:767–776. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
He X, Hong Y, Wang X, Zhang X, Long J, Li
H, Zhang B, Chen S, Liu Q, Li H, et al: Identification and clinical
significance of an elevated level of serum aminoacylase-1
autoantibody in patients with hepatitis B virus-related liver
cirrhosis. Mol Med Rep. 14:4255–4262. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li F, Yan H, Wang J, Li C, Wu J, Wu S, Rao
S, Gao X and Jin Q: Non-invasively differentiating extent of liver
fibrosis by visualizing hepatic integrin αvβ3 expression with an
MRI modality in mice. Biomaterials. 102:162–174. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ma W, Kang F, Wang Z, Yang W, Li G, Ma X,
Li G, Chen K, Zhang Y and Wang J: 99mTc-labeled
monomeric and dimeric NGR peptides for SPECT imaging of CD13
receptor in tumor-bearing mice. Amino Acids. 44:1337–1345. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Berman JJ: Tumor classification: Molecular
analysis meets Aristotle. BMC Cancer. 4:102004. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Pantel AR and Mankoff DA: Molecular
imaging to guide systemic cancer therapy: Illustrative examples of
PET imaging cancer biomarkers. Cancer Lett. 387:25–31. 2017.
View Article : Google Scholar : PubMed/NCBI
|
